New Publication: Real-world comparative effectiveness of 2nd line ipilimumab for metastatic melanoma…
ARCC and the CanREValue Collaboration are excited to share our recent study, using Ontario based real-world data to generate real-world evidence on the comparative effectiveness of 2nd line ipilimumab. Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada Dai WF, Beca JM, Croxford (more…)
Connect With Us!